Prajak J. Barde

What to use to express the variability of data: Standard deviation or standard error of mean?

Prajak J. Barde, MohiniP Barde · Perspectives in Clinical Research · 2012 · 281 citations · Full text

Natural Sciences, Biomedical Sciences, Biostatistics +16

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Auris Huen, Bradley M. Haverkos, Jasmine M. Zain et al. · Cancers · 2020 · 63 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +15

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study

Carmelo Carlo‐Stella, Richard Delarue, Lydia Scarfò et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 26 citations

Medicine, Hematology, Pharmacology +9

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study

Swaminathan P. Iyer, Auris Huen, Weiyun Z. Ai et al. · Haematologica · 2023 · 23 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A first‐in‐human study to evaluate the safety, tolerability and pharmacokinetics of RP3128, an oral calcium release‐activated calcium (CRAC) channel modulator in healthy volunteers

Prajak J. Barde, Srikant Viswanadha, Sridhar Veeraraghavan et al. · Journal of Clinical Pharmacy and Therapeutics · 2020 · 18 citations

Medicine, Pharmacokinetics, Pharmacology +12